The short version of bremelanotide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-14 and is reviewed periodically as new material appears.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4 melanocortin receptor | Other melanocortin subtypes are also activated |
| Typical route in approved use | Subcutaneous injection | Single-use format in the marketed product |
| Elimination half-life | Roughly two to three hours | Short exposure supports as-needed use |
| Common adverse events | Nausea, flushing, headache | Generally transient but can be dose limiting |
| Main studied group | Premenopausal women with low desire | Controlled data outside this group are limited |
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
demonstrated DE sorting and isolation on-chip followed by FACS that allows for high sorting throughput of encapsulated mammalian cells, from which genetic material can later be extracted. While fluorogenic labeling is a powerful tool for tracking and sorting, it is not always compatible with droplet-based microfluidic systems and experimental design. New label-free and non-fluorescence-based detection techniques have recently been reported. In 2016, Gielen et al. published an absorbance-activated droplet sorting (AADS) microfluidic device and demonstrated its functionality by directing the evolution of a phenylalanine dehydrogenase. In 2016, Sun et al. demonstrated the use of SE droplets and high-throughput MS to screen enzyme activators and inhibitors by screening a transaminase library. In 2019, Pan et al. showed sorting of droplets by interfacial tensions, which are affected by droplet content. In 2020, Haidas et al. presented a microfluidic approach that uses both matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) and fluorescence microscopy, which the authors used to measure the concentration and activity of phytase, respectively, in yeast cells. In 2020, Holland-Moritz et al. published their mass activated droplet sorting (MADS) method, which integrates MS analysis with fluorescence-activated droplet sorting (FADS). Using this method, droplets are split and analyzed separately by both MS and FADS. The power of this method was demonstrated by screening the activity of a transaminase library expressed in vitro.
=== Other uses in science and technology === Cathodic protection, a technique used to control the corrosion of a metal surface Cellphone, a portable telephone device Clock pulse, a signal type in electronics Complementizer phrase, in linguistics, the syntactic head of a full clause Continental Polar (cP), in meteorology, a type of air mass Control point, a section of track where switches and signals control trains within a centralized traffic control
Whites owned most of the best farmland, and had far superior education, wages and homes, but the schooling, healthcare, infrastructure and salaries available to black Rhodesians were nevertheless very good by African standards. In the wider Imperial context, Southern Rhodesia occupied a category unto itself because of the "special quasi-independent status" it held. The Dominions Office, formed in 1925 to handle British relations with the dominions of Australia, Canada, New Zealand, Newfoundland, South Africa and the Irish Free State (the Statute of Westminster 1931 delineated the rights of the dominions more clearly in that year), also dealt with Southern Rhodesia, and Imperial Conferences included the Southern Rhodesian Prime Minister alongside those of the dominions from 1932. This unique arrangement continued following the advent of Commonwealth Prime Ministers' Conferences in 1944. Southern Rhodesians of all races fought for Britain in the Second World War, and the colonial government gradually received more autonomy regarding external affairs. During the immediate post-war years, Southern Rhodesian politicians generally thought that they were as good as independent as they were, and that full autonomy in the form of dominionship would make little difference to them. Post-war immigration to Southern Rhodesia, mainly from Britain, Ireland and South Africa, caused the white community to swell from 68,954 in 1941 to 221,504 in 1961. The black population grew from 1,400,000 to 3,550,000 over the same period.
Sources: en.wikipedia.org
The two substrates of this enzyme are (R,R)-butane-2,3-diol and NAD+; its products are (R)-acetoin, nicotinamide adenine dinucleotide (NADH), and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (R,R)-butane-2,3-diol:NAD+ oxidoreductase. Other names in common use include butyleneglycol dehydrogenase, D-butanediol dehydrogenase, D-(−)-butanediol dehydrogenase, butylene glycol dehydrogenase, diacetyl (acetoin) reductase, D-aminopropanol dehydrogenase, D-aminopropanol dehydrogenase, 1-amino-2-propanol dehydrogenase, 2,3-butanediol dehydrogenase, D-1-amino-2-propanol dehydrogenase, (R)-diacetyl reductase, (R)-2,3-butanediol dehydrogenase, D-1-amino-2-propanol:NAD+ oxidoreductase, 1-amino-2-propanol oxidoreductase, and aminopropanol oxidoreductase. This enzyme participates in butanoic acid metabolism.
=== Removing plastics from oceans === One innovation of green nanotechnology that is currently under development are nanomachines modeled after a bacterium bioengineered to consume plastics, Ideonella sakaiensis. These nano-machines are able to decompose plastics dozens of times faster than the bioengineered bacteria not only because of their increased surface area but also because the energy released from decomposing the plastic is used to fuel the nano-machines.
=== Discovery and development === Aptamers were originally discovered in 1990 when Lary Gold and Craig Tuerk utilized a method of directed evolution known as SELEX to isolate a small single stranded RNA molecule that was capable of binding to T4 bacteriophage DNA polymerase. Additionally, the term “aptamer” was coined by Andrew Ellington, who worked with Jack Szostak to select an RNA aptamer that was capable of tight binding to certain organic dye molecules. The term itself is a conglomeration of the Latin “aptus” or “to fit” and the Greek “meros” or “part." RNA aptamers are not so much “created” as “selected.” To develop an RNA aptamer capable of selective binding to a molecular target, a method known as Systematic Evolution of Ligands by EXponential Enrichment (SELEX) is used to isolate a unique RNA aptamer from a pool of ~10^13 to 10^16 different aptamers, otherwise known as a library. The library of potential aptamer oligonucleotides is then incubated with a non-target species so as to remove aptamers that exhibit non-specific binding. After subsequent removal of the non-specific aptamers, the remaining library members are then exposed to the desired target, which can be a protein, peptide, cell type, or even an organ (in the case of live animal-based SELEX). From there, the RNA aptamers which were bound to the target are transcribed to cDNA which then is amplified through PCR, and the PCR products are then re-transcribed to RNA.
A live recording from the Canadian leg of the tour was released at the end of February 2016 as Live In Toronto, which included the new songs "Radical Action (To Unseat the Hold of Monkey Mind)" and "Meltdown". A European tour was planned for 2016. Following Rieflin's decision to take a break from music, drummer Jeremy Stacey of Noel Gallagher's High Flying Birds was called in place for dates from September.
Sources: en.wikipedia.org
The reduction and subsequent reoxidation of vitamin K coupled with carboxylation of Glu is called the vitamin K cycle. Humans are rarely deficient in vitamin K because, in part, vitamin K2 is continuously recycled in cells. Warfarin and other 4-hydroxycoumarins block the action of VKOR. This results in decreased concentrations of vitamin K and vitamin K hydroquinone in tissues, such that the carboxylation reaction catalyzed by the glutamyl carboxylase is inefficient. This results in the production of clotting factors with inadequate Gla. Without Gla on the amino termini of these factors, they no longer bind stably to the blood vessel endothelium and cannot activate clotting to allow formation of a clot during tissue injury. As it is impossible to predict what dose of warfarin will give the desired degree of clotting suppression, warfarin treatment must be carefully monitored to avoid underdose and overdose.
Raleigh is home to a wide variety of religious practitioners. The predominant religion in Raleigh is Christianity, with the largest numbers of adherents being Baptist (14.1%), Methodist (5.6%), and Roman Catholic (4.2%). Others include Presbyterianism (2.8%), Pentecostalism (1.7%), Anglicanism/Episcopalianism (1.2%), Lutheranism (0.6%), the Latter-Day Saints (0.7%), and other Christian denominations (10.2%) including the Eastern Orthodox, Oriental Orthodox, Jehovah's Witness, Christian Science, Christian Unitarianism, other Mainline Protestant groups, and non-denominational Christians. The Roman Catholic Diocese of Raleigh, the Episcopal Diocese of North Carolina, the Coptic Orthodox Diocese of South Carolina, North Carolina, and Kentucky, the North Carolina Annual Conference of the United Methodist Church, and the New Hope Presbytery of the Presbyterian Church (USA) are all headquartered in Raleigh. Other religions, including Hinduism, Buddhism, Baháʼí, Druze, Taoism, and Shintoism make up 1.31% of religious practitioners. Judaism (0.9%) and Islam (0.8%) are also practiced. In Wake County, 29% of the population are affiliated with the Southern Baptist Convention, 22% are affiliated with the Catholic Church, 17% are affiliated with the United Methodist Church, 6% are affiliated with the Presbyterian Church (USA), and 27% are religiously affiliated with other denominations, religions, or are not religiously affiliated.
Only 1–2% of Alzheimer's cases are inherited due to autosomal dominant mutations, as Alzheimer's disease is substantially polygenic. When autosomal dominant variants cause the disease, it is known as early-onset familial Alzheimer's disease, which is rarer and tends to progress more rapidly. Less than 5% of sporadic Alzheimer's disease have an earlier onset, and early-onset Alzheimer's is about 90% heritable. Familial Alzheimer's disease usually implies two or more persons affected in one or more generations. Early onset familial Alzheimer's disease can be attributed to mutations in one of three genes: those encoding amyloid-beta precursor protein (APP) and presenilins PSEN1 and PSEN2. Most mutations in the APP and presenilin genes increase the production of a small protein called amyloid beta (Aβ)42, which is the main component of amyloid plaques. Some of the mutations merely alter the ratio between Aβ42 and the other major forms—particularly Aβ40—without increasing total Aβ levels in the brain. Two other genes associated with autosomal dominant Alzheimer's disease are ABCA7 and SORL1. Alleles in the TREM2 gene have been associated with a three to five times higher risk of developing early-onset Alzheimer's disease. A Japanese pedigree of early-onset familial Alzheimer's disease was found to be associated with a deletion mutation of codon 693 of APP. This mutation and its association with Alzheimer's disease was first reported in 2008, and is known as the Osaka mutation. Only homozygotes with this mutation have an increased risk of developing Alzheimer's disease.
Sources: en.wikipedia.org
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.
It means the product is taken shortly before anticipated activity instead of every day. This pattern reduces total exposure and shapes how safety monitoring is planned. It also means effects are expected to be temporary rather than cumulative.
Desire is assessed through validated self-report questionnaires, sometimes paired with event counts and a distress scale. These instruments capture subjective experience, so results depend on how participants interpret the questions. No laboratory marker currently substitutes for such reporting.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.